186Re-HEDP for metastatic bone pain in breast cancer patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue SUPPL. 1, 2004, Pages

  Lam, Marnix G E H ^a   De Klerk, John M H ^a,b   Van Rijk, Peter P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Bone metastases; Breast cancer; Pain palliation; Radionuclide therapy; Rhenium

Indexed keywords

ETIDRONIC ACID RE 186; RADIOPHARMACEUTICAL AGENT; ETIDRONIC ACID; ORGANOMETALLIC COMPOUND; RHENIUM; RHENIUM-186 HEDP;

ANALGESIA; BLOOD TOXICITY; BODY MOVEMENT; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG HALF LIFE; DRUG SAFETY; EARLY DIAGNOSIS; FEMALE; HUMAN; INDEPENDENCE; LEUKOPENIA; PAIN ASSESSMENT; PALLIATIVE THERAPY; PATIENT MOBILITY; PRESSURE; QUALITY OF LIFE; RADIATION FIELD; RADIOISOTOPE DISTRIBUTION; REVIEW; SOCIAL ADAPTATION; THROMBOCYTOPENIA; BONE TUMOR; BREAST TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; METHODOLOGY; PAIN; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

BONE NEOPLASMS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; ETIDRONIC ACID; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; ORGANOMETALLIC COMPOUNDS; PAIN; PALLIATIVE CARE; RADIATION INJURIES; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RHENIUM; TREATMENT OUTCOME;

EID: 3042623522     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1539-4     Document Type: Review

References (36)

1. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993; 20:66-74.
2. Mathieu L, Chevalier P, Galy G, Berger M. Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms. Int J Appl Radiat Isot 1979; 30:725-727.
3. Deutsch E, Libson K, Vanderheyden JL, Ketring AR, Maxon HR. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl Instrum B 1986; 13:465-477.
4. de Klerk JM, van Dijk A, het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992; 33:646-651.
5. de Klerk JM, Zonnenberg BA, het Schip AD, et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21:1114-1120.
6. de Klerk JM, Zonnenberg BA, Krouwer HG, et al. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment. J Nucl Med 1996; 37:465-467.
7. de Klerk JM, het Schip AD, Zonnenberg BA, et al. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 1996; 37:244-249.
8. Englaro EE, Schroder LE, Thomas SR, et al. Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients. Clin Nucl Med 1992; 17:41-44.
9. de Klerk JM, het Schip AD, Zonnenberg BA, et al. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. J Nucl Med 1994; 35:1423-1428.
10. 186Re- etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002; 43:1150-1156.
11. Maxon HR III, Thomas SR, Hertzberg VS, et al. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med 1992; 22:33-40.
12. de Klerk JM, van Dieren EB, het Schip AD, et al. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med 1996; 37:38-41.
13. Israel O, Keidar Z, Rubinov R, et al. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186-etidronate. J Clin Oncol 2000; 18:2747-2754.
14. Maxon HR III, Schroder LE, Thomas SR, et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990; 176:155-159.
15. 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 2000; 41:647-654.
16. 186Re-etidronate in breast cancer patients with metastatic bone pain. J Nucl Med 1999; 40:639-642.
17. Quirijnen JM, Han SH, Zonnenberg BA, et al. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med 1996; 37:1511-1515.
18. Sciuto R, Festa A, Pasqualoni R, et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 2001; 66:101-109.
19. 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer, J Nucl Med 2000; 41:1689-1694.
20. Palmedo H, Bender H, Dierke-Dzierzon C, et al. Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. Clin Nucl Med 1999; 24:643-648.
21. Limouris GS, Shukla SK, Condi-Paphiti A, et al. Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases. Anticancer Res 1997; 17:1767-1772.
22. Schoeneich G, Palmedo H, Dierke-Dzierzon C, Muller SC, Biersack HJ. Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results. Scand J Urol Nephrol 1997; 31:445-448.
23. Hauswirth AE, Palmedo H, Dierke-Dzierzon C, Biersack HJ, Krebs D. Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP [in German]. Zentralbl Gynakol 1998; 120:83-86.
24. Kucuk NO, Ibis E, Aras G, et al. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases. Ann Nucl Med 2000; 14:239-245.
25. Tennvall J, Abrahamsson PA, Ahlgren G, et al. Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate) in patients with hormone-refractory disseminated prostate carcinoma. Scand J Urol Nephrol 2000; 34:188-193.
26. Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001; 28:788-798.
27. Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases [in German]. Nuklearmedizin 2000; 39:146-151.
28. Guerra UP, Englaro E, Cattaruzzi E. Palliative therapy with rhenium-186-HEDP for bone metastases of breast cancer. Tumori 1997; 83:560-562.
29. Limouris G, Shukla SK, Manetou A, et al. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer. Anticancer Res 1997; 17:1699-1704.
30. Virotta G, Medolago G, Arrigoni S, Butti I, Bertocchi C. Rhenium-186 hydroxyethylidene diphosphonate for treatment of painful osseous metastases from mammary carcinoma. Tumori 1997; 83:563-565.
31. Holle LH, Humke U, Trampert L, Ziegler M, Kirsch CM, Oberhausen E. Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP). Urologe A 1997; 36:540-547.
32. Giannakenas C, Kalofonos HP, Apostolopoulos DJ, Zarakovitis J, Kosmas C, Vassilakos PJ. Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease. Am J Clin Oncol 2000; 23:83-88.
33. McCready VR, O'Sullivan JM. Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med Mol Imaging 2002; 29:1271-1275.
34. O'Sullivan JM, McCready VR, Flux G, et al. High activity rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 2002; 86:1715-1720.
35. m-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents. Nucl Med Commun 1999; 20:875-881.
36. 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002; 62:3120-3125.